Colchicine drug interactions | Litt's Drug Eruption and Reaction Database

Colchicine

TRADE NAMES: ColBenemid; Colchiquim; Colcrys; Colgout; Goutnil; Kolkicin; Konicine
INDICATIONS: Gouty arthritis (in adults), gout, familial Mediterranean fever
CLASS: Alkaloid, Anti-inflammatory, COVID-19 putative drug
HALF-LIFE: 27–31 hours (following multiple doses)

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Amiodarone, Aprepitant, Atazanavir, Atorvastatin, Azithromycin, Boceprevir, Clarithromycin, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Alafenamide, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil, Conivaptan, Cyanocobalamin, Cyclosporine, Darunavir, Dasatinib, Delavirdine, Digoxin, Diltiazem, Efavirenz, Erythromycin, Fenofibrate, Fibrates, Fluvastatin, Gemfibrozil, Grapefruit Juice, HMG-CoA reductase inhibitors, Indinavir, Itraconazole, Ketoconazole, Lapatinib, Lopinavir, Ombitasvir/Paritaprevir/Ritonavir, P-glycoprotein inhibitors or inducers, Pravastatin, Protease inhibitors, Ritonavir, Rosuvastatin, Saxagliptin, Simvastatin, Strong CYP3A4 inhibitors, Telithromycin, Troleandomycin, Verapamil, Voriconazole

PREGNANCY CATEGORY: C

Under investigation for treating COVID-19

See adverse reactions attributed to class:

COVID-19 putative drug

Contra-indicated in patients with renal or hepatic impairment where P-glycoprotein or strong CYP3A4 inhibitors are also prescribed.

Behçet's disease

(2003): Fujii Y+, Ryumachi Feb 43(1), 44

Bullous dermatitis <1%

(1957): Ott H+, Dtsch Med Wochenschr (German) 82, 1163

Erythema nodosum

(2002): Guven AG+, Pediatrics 109(5), 971

Erythroderma

(1971): Durkalec J+, Pol Tyg Lek (Polish) 26, 1048

Exanthems

(2006): Mason SE+, J Cutan Pathol 33(4), 309 (violaceous)

Fixed eruption

(1996): Mochida K+, Dermatology 192, 61

Lichenoid eruption

(1974): Sayag J+, Bull Soc Fr Dermatol Syphiligr (French) 81, 94

Photosensitivity

(1992): Foti C+, Contact Dermatitis 27, 201

Pruritus (itching) <1%

(1957): Hollander L, Arch Dermatol 75, 872

(1957): Ott H+, Dtsch Med Wochenschr (German) 82, 1163

Pyoderma

(1957): Ott H+, Dtsch Med Wochenschr (German) 82, 1163

Rash <1%

(package insert)

Staphylococcal scalded skin syndrome

(1993): Khuong MA+, Dermatology 186, 153

(1967): Halprin KM, JAMA 202, 137

Toxic epidermal necrolysis

(2004): Arroyo MP+, Br J Dermatol 150(3), 581

(1994): Alfandari S+, Infection 22, 365

(1990): Roujeau JC+, Arch Dermatol 126, 37

Urticaria

(1991): Anderson MH+, Ann Allergy 66, 207 [REVIEW]

Vasculitis

(1993): Barash J+, Isr J Med Sci 29, 310

(1964): Sinaly NP, Ann Intern Med 60, 470

Vesiculation

(palms)

(1957): Hollander L, Arch Dermatol 75, 872

Alopecia <10%

(2004): Rollot F+, Ann Pharmacother 38(12), 2074 (with erythromycin, clarithromycin)

(2002): Guven AG+, Pediatrics 109(5), 971

(1980): Harms M, Hautarzt (German) 31, 161

(1977): Naidus RM+, Arch Intern Med 137, 394

(1970): Wallace S+, Am J Med 48, 443

(1967): Spanopoulos GJ, Practitioner 198, 426

Central Nervous System

Dysesthesia

(2005): Sugie M+, No To Shinkei 57(9), 785 [REVIEW] (with bezafibrate)

Fever (pyrexia)

(2004): Rollot F+, Ann Pharmacother 38(12), 2074 (with erythromycin, clarithromycin)

Headache 2%

(package insert)

Neurotoxicity

(2015): Herscovici T+, Breastfeed Med 10(2), 92 (in breasted infants)

(2015): Su YC+, Drug Saf Case Rep 2(1), 16 [REVIEW] (with fluconazole)

(2008): van der Velden W+, Neth J Med 66(5), 204 (with clarithromycin)

Endocrine/Metabolic

Porphyria cutanea tarda

(1971): Kuokkanen K, Acta Derm Venereol (Stockh) 51, 318

Gastrointestinal/Hepatic

Abdominal pain <20%

(2014): Alabed S+, Cochrane Database Syst Rev 8, CD010652 [REVIEW]

(2004): Rollot F+, Ann Pharmacother 38(12), 2074 (with erythromycin, clarithromycin)

Diarrhea 23%

(2019): Goldberg O+, Semin Arthritis Rheum May, Epub ahead of print23–24%

(2019): Tardif JC+, N Engl J Med Nov, Epub ahead of print10%

(2017): Schlesinger N, Expert Opin Drug Saf 16(4), 429 [REVIEW]

(2014): Alabed S+, Cochrane Database Syst Rev 8, CD010652 [REVIEW]

(2014): van Echteld I+, Cochrane Database Syst Rev 8, CD006190 [REVIEW]

(2014): Wang Y+, Int J Med Sci 11(9), 88024%

(2012): Padeh S+, J Pediatr 161(6), 1142

(2010): Terkeltaub RA+, Arthritis Rheum 62 (4), 1060

Gastrointestinal adverse reaction

(2020): Ullah W+, Cardiovasc Revasc Med Jun, Online ahead of print [REVIEW]

Gastrointestinal disorder

(2014): Panarelli NC, Semin Diagn Pathol 31(2), 165 [REVIEW]

(2013): Nidorf SM+, J Am Coll Cardiol 61(4), 404

Hepatotoxicity

(2014): De Petris G+, Int J Surg Pathol 22(2), 120 [REVIEW]

(2014): Panarelli NC, Semin Diagn Pathol 31(2), 165 [REVIEW]

(2012): Todd BA+, Pharmacotherapy 32(11), 974

Nausea <20%

(2017): Schlesinger N, Expert Opin Drug Saf 16(4), 429 [REVIEW]

(2014): van Echteld I+, Cochrane Database Syst Rev 8, CD006190 [REVIEW]

(2014): Wang Y+, Int J Med Sci 11(9), 8805%

Vomiting <20%

(2017): Schlesinger N, Expert Opin Drug Saf 16(4), 429 [REVIEW]

(2014): van Echteld I+, Cochrane Database Syst Rev 8, CD006190 [REVIEW]

(2014): Wang Y+, Int J Med Sci 11(9), 8801%

(2010): Terkeltaub RA+, Arthritis Rheum 62 (4), 1060

Leukocytopenia (leukopenia)

(2012): Beggs AE+, Am J Health Syst Pharm 69(24), 2147 (long-term administration)

Thrombocytopenia

(2015): Solomon LR, Acta Oncol 54(8), 1235 (low-dose / with nivolumab)

Neuromuscular/Skeletal

Asthenia (fatigue) <4%

(2007): Altman A+, Clin Rheumatol 26 (12), 2197

Gouty tophi 4%

(package insert)

Myalgia/Myositis/Myopathy/Myotoxicity

(2017): Guemara R+, Rev Med Suisse (French) 13(562), 1013

(2017): Siriangkhawut M+, Saudi Pharm J 25(6), 823 (with simvastatin)

(2012): Ferrie B+, Therapie 67(5), 482 (severe)

(2012): Oh DH+, Med J Aust 197(6), 332 (with simvastatin)

(2009): Lonesky TA+, J Rheumatol 36(11), 2617

(2007): Altman A+, Clin Rheumatol 26 (12), 2197

(2007): Justiniano M+, J Clin Rheumatol 13 (5), 266

(2005): Alayli G+, Ann Pharmacother 39(7-8), 1358 (with pravastatin)

(2005): Sugie M+, No To Shinkei 57(9), 785 [REVIEW] (with bezafibrate)

(2002): Atmaca H+, Ann Pharmacother 36(11), 1719 (with gemfibrozil)

(2002): Ayllon-Munoz JA+, Rev Neurol 35(2), 195

(2002): Caglar K+, Nephron 92(4), 922

(2002): Fernandez C+, Acta Neuropathol (Berlin) 103(2), 100

(2002): Guven AG+, Pediatrics 109(5), 971

(2002): Hsu WC+, Clin Neuropharmacol 25(5), 266 (with simvastatin)

(1999): Gruberg L+, Transplant Proc 31, 2157

(1998): Duarte J+, Muscle Nerve 21, 550

(1997): Ducloux D+, Nephrol Dial Transplant 12, 2389

(1997): Sinsawaiwong S+, J Med Assoc Thai 80, 667

(1992): Himmelmann F+, Acta Neuropathologica 83, 440

Rhabdomyolysis

(2017): Schlesinger N, Expert Opin Drug Saf 16(4), 429 [REVIEW]

(2015): Cohen O+, Rheumatol Int 35(11), 1937 (with clarithromycin)

(2013): Kim JB+, J Clin Rheumatol 19(2), 108 (with clarithromycin)

(2009): McKinnell J+, J Clin Rheumatol 15 (6), 303 (with clarithromycin)

(2007): Altman A+, Clin Rheumatol 26 (12), 2197

(2007): Justiniano M+, J Clin Rheumatol 13 (5), 266 (with simvastatin)

(2006): Tufan A+, Ann Pharmacother 40(7-8), 1466 (with atorvastatin)

(2006): Varughese GI+, Nephrology (Carlton) 11(5), 481

(2005): Atasoyu EM+, Ann Pharmacother, 1368 (with fluvastatin)

(2004): Baker SK+, Muscle Nerve 30(6), 799 (with simvastatin)

(2003): Phanish MK+, Am J Med 114(2), 166

(2003): Vasudevan AR+, Am J Med 115(3), 249

(2002): Atmaca H+, Ann Pharmacother 36(11), 1719 (with gemfibrozil)

(2002): Boomershine KH, Ann Pharmacother 36(5), 824

(2001): Chattopadhyay I+, Postgrad Med J 77(905), 191

(1998): Rosset L+, Schweiz Med Wochenschr 128(49), 1953

(1997): Dawson TM+, J Rheumatol 24(10), 2045

(1992): Stefanidis I+, Dtsch Med Wochenschr 117(33), 1237

Nephrotoxicity

(2005): Krysiak R+, Pol Arch Med Wewn 114(3), 882

Pharyngolaryngeal pain 3%

(package insert)

Pneumonia

(2019): Tardif JC+, N Engl J Med Nov, Epub ahead of print<1% (serious)

Adverse effects

(2017): Papageorgiou N+, Cardiovasc Ther 35(1), 10 [REVIEW]

(2015): Raval J+, Heart Lung Circ 24(7), 660 [REVIEW]

(2014): Eun J+, Am J Health Syst Pharm 71(15), 1277 [REVIEW] (gastrointestinal)

(2014): Imazio M+, JAMA 312(10), 101620% (gastrointestinal)

(2014): Stamp LK, Curr Opin Rheumatol 26(2), 162 [REVIEW]

(2014): van Echteld I+, Cochrane Database Syst Rev 8, CD006190 [REVIEW]

Allergic reactions

(2001): Vittori F+, Therapie 56(1), 63

Death

(2006): Huynh-Do U, Ther Umsch 63(12), 783

(2002): Maxwell MJ+, Emerg Med J 19(3), 265 (overdose)

(2002): Sannohe S+, J Forensic Sci 47(6), 1391 (overdose)

Intoxication

(2009): Le Bellec ML+, Rev Med Interne 30 (9), 783 (4 elderly women)

Multiorgan failure

(2012): Ucgul A+, Ir J Med Sci 181(2), 295

Side effects 14%

(1957): Ott H+, Dtsch Med Wochenschr (German) 82, 1163

Adverse reactions attributed to entire drug class COVID-19 putative drug

Cutaneous adverse reaction

(2020): Tursen U+, Dermatol Ther May, Epub ahead of print [REVIEW]

Cardiovascular adverse effect

(2020): Carpenter A+, Front Cardiovasc Med 7, 85 [REVIEW]

(2020): Giudicessi JR+, Mayo Clin Proc May, Online ahead of print [REVIEW]

(2020): Naksuk N+, Eur Heart J Acute Cardiovasc Care May, Epub ahead of print [REVIEW]

(2020): Sarayani A+, Res Social Adm Pharm Apr, Epub ahead of print [REVIEW]

(2020): Zhang D+, Zhongguo Zhong Yao Za Zhi (Chinese) 45(10), 2275-2286 [REVIEW]

Gastrointestinal/Hepatic

Gastrointestinal disorder

(2020): Sun J+, Clin Pharmacol Ther Apr, Epub ahead of print23%

Hepatic disorder

(2020): Sun J+, Clin Pharmacol Ther Apr, Epub ahead of print14%

Thrombocytopenia

(2020): Nham E+, Infect Chemother Apr, Epub ahead of print

Adverse effects

(2020): Favilli A+, J Matern Fetal Neonatal Med Jun, Online ahead of print [REVIEW]

(2020): Griffiths G+, Trials 21(1), 544

(2020): Patil VM+, Life Sci May, Epub ahead of print [REVIEW]

(2020): Rhodes NJ+, medRxiv Jun, Preprint

(2020): Sun J+, Clin Pharmacol Ther Apr, Epub ahead of print38%

(2020): Svensson M, Lakartidningen (Swedish) Apr, 117

(2020): Wen CY+, Zhonghua Nei Ke Za Zhi (Chinese) May, Epub ahead of print

(2020): Zhong H+, Pharmacol Res Apr, Epub ahead of print [REVIEW]

Page last updated 06/25/2020

Drug Eruption Mobile Site

Symbol key

Incidence

<1%
1-5%
5-10%
10-15%
15-20%
20-30%
>30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

Breast feeding
Geriatric
Pediatric

^ Back to top